Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Guggenheim

Guggenheim lowered shares of Keros Therapeutics (NASDAQ:KROS) from a buy rating to a neutral rating in a research note issued to investors on Monday, Marketbeat.com reports.

Other equities research analysts have also recently issued reports about the stock. Scotiabank dropped their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research report on Friday. Wells Fargo & Company lifted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Wedbush reaffirmed an “outperform” rating and set a $84.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Finally, HC Wainwright reduced their price objective on Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $81.33.

Keros Therapeutics Stock Up 3.1 %

Shares of Keros Therapeutics stock opened at $19.42 on Monday. The business’s fifty day moving average is $58.29 and its two-hundred day moving average is $52.50. Keros Therapeutics has a fifty-two week low of $15.67 and a fifty-two week high of $73.00. The firm has a market cap of $786.65 million, a PE ratio of -3.73 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the business earned ($1.33) earnings per share. Equities research analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Investors Weigh In On Keros Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. boosted its stake in shares of Keros Therapeutics by 14.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 260,120 shares of the company’s stock worth $15,105,000 after acquiring an additional 32,492 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of Keros Therapeutics in the second quarter worth $1,118,000. Intech Investment Management LLC acquired a new position in Keros Therapeutics in the third quarter valued at about $603,000. Bank of New York Mellon Corp lifted its position in Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock worth $5,410,000 after purchasing an additional 18,755 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in Keros Therapeutics by 155.9% during the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares in the last quarter. 71.56% of the stock is owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.